


Vyome Holdings, Inc. (HIND)

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001427570

Vyome Holdings, Inc.					
HIND; healthcare					
Grade	E				
weakest fifth of 371 graded peers percentile 97.8; sampling error 2.5 points; lower is stronger					
Rank	363 of 371				
Profitability	C/D	 percentile 62.5			
Solvency	D/E	 percentile 80.3			
Growth and financing	E	 percentile 91.6			
Reliability	0.76 AUC filers with under \$12.5M assets; 95% interval 0.65 to 0.86; 63 events, 2020 to 2025				
Peer failure rate	0.60% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025				
Size band	under \$12.5M assets total assets \$6.5M				
Standard universe	outside revenue above \$1M and assets above \$10M				
Warnings	dilution, late filer; fortress balance sheet not computable: distress				
Inputs computable	8 of 14				
Graded from	filings received through Mar 18, 2026 205 days before the rescans; latest periodic filing 10-Q received Aug 12, 2026				
Last close	\$2.03 2026-10-07; market equity \$14.2M				
Price used in grade	None				



E, the bear
weakest fifth of its sector;
letters are fifths of the 371
graded peers

Share price, twelve months to the rescans
split-adjusted close; the letter is fixed at the rescans that set it



Rescans on file: E from Mar 21, 2021, E from Apr 21, 2022, E from Apr 21, 2023

Letter at every rescans

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Mar 18, 2026

Lifesciences Inc. (now known as Vyome Holdings, Inc.) (the "Company") completed the merger pursuant to the Agreement and Plan of Merger, dated as of July 8, 2024, as amended (the "Merger Agreement"), by and among the Company, Raider Lifesciences Inc., a wholly owned subsidiary of the Company ("Merger Sub"), and Vyome Therapeutics, Inc. ("Vyome"). Pursuant to the Merger Agreement, Merger Sub merged with and into Vyome, with Vyome surviving the merger as a subsidiary of the Company (the

"Merger"). As a result of the Merger, the Company was renamed "Vyome Holdings, Inc.

The fourteen inputs


lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 62.5						
Gross profitability		3.4%	32.2%	87.6	372	2025-12-31
Return on invested capital		not computable	9.3%			required facts have no common fiscal period end
Accruals ratio		(165.3%)	(6.6%)	2.7	811	2025-12-31
Gross margin stability, five years		24.6 pts	2.8 pts	97.1	243	2025-12-31
Solvency, sleeve percentile 80.3						
Twelve-month failure probability		not computable	0.07%			latest liabilities, cash plus short-term investments, book equity, and shares are required
Altman Z double-prime		(50.57)	(0.31)	88.7	756	2025-12-31
Net debt to EBITDA		not computable	1.82x			required facts have no common fiscal period end
Interest coverage		not computable	(4.51x)			one or more required annual facts are missing
Current ratio		1.99x	2.96x	72.0	839	2025-12-31
Growth and financing, sleeve percentile 91.6						
Revenue growth, three-year compound		(69.5%)	10.0%	97.8	415	2025-12-31
Free cash flow growth, three-year compound		not computable	10.9%			four consecutive annual FCF observations are required; found 7
Reinvestment rate		not computable	37.1%			pretax income must exceed the validity floor and imply a 0%-100% tax rate
Asset growth, three years		(16.5%)	2.1%	78.1	704	2025-12-31
Net share issuance, one year		6,124.2%	2.5%	98.9	634	2026-03-17

Warnings

3 of 7 checks triggered; none of them enters the letter

Check	Measured
Dilution	split-adjusted year-over-year share growth is 6124.2%
Late filer	found 2 NT 10-K/Q filings in the last eight quarters
Fortress balance sheet	cash minus debt is 11,257,000 USD; Altman Z is not used



Rank	Company	Percentile	Letter	Warnings
358	Dare Bioscience, Inc. (DARE)	96.5	E	dilution
359	Longeveron Inc. (LGVN)	96.8	E	short runway
360	Clene Inc. (CLNN)	97.0	E	dilution,
				distress
361	Agenus Inc. (AGEN)	97.3	E	dilution, short
				runway
362	Nektar Therapeutics (NKTR)	97.6	E	dilution, short
				runway
363	Vyome Holdings, Inc. (HIND) <	97.8	E	dilution, late
				filer, fortress
				balance sheet
364	Sintx Technologies, Inc. (SINT)	98.1	E	dilution, short
				runway
365	Coherus Oncology, Inc. (CHRS)	98.4	E	dilution, short
				runway
366	Alector, Inc. (ALEC)	98.6	E	short runway,
				fortress
				balance sheet
367	Atara Biotherapeutics, Inc. (ATRA)	98.9	E	dilution, short
				runway
368	HCW Biologics Inc. (HCWB)	99.2	E	dilution, short
				runway, late
				filer,
				degenerate
				inputs,
				fortress
				balance sheet

What the price implies

at the 2026-10-07 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(58.3%)	8.0%	11
Distance from 52-week high	(67.8%)	(31.4%)	12
EBIT to enterprise value	(111.7%)	(1.5%)	5
Free cash flow yield	(119.3%)	(1.0%)	5
Book value to price	0.51	0.28	70
Sales to price	0.02	0.31	9
Composite equity issuance, five years	1,332.0%	20.3%	99
Relative strength against the sector, log excess return	(1.09)	(0.14)	11

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	pass
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	\$7.9M
Operating cash flow, four quarters	-\$5.6M
Months of runway	17.0
Days since last periodic filing	58 (10-Q received Aug 12, 2026)
Median daily dollar volume, 63 sessions	\$16,258

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	\$218,771	2025-12-31	2026-03-18	10-K	0001213900-26-029500
2	assets	us-gaap:Assets	\$6.5M	2025-12-31	2026-03-18	10-K	0001213900-26-029500
3	net income	us-gaap:NetIncomeLoss	-\$10.3M	2025-12-31	2026-03-18	10-K	0001213900-26-029500
4	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$3.7M	2025-12-31	2026-03-18	10-K	0001213900-26-029500
5	assets	us-gaap:Assets	\$1.4M	2024-12-31	2026-03-18	10-K	0001213900-26-029500
6	revenue	us-gaap:Revenues	\$319,714	2025-12-31	2026-03-18	10-K	0001213900-26-029500
7	gross profit	us-gaap:GrossProfit	\$194,970	2024-12-31	2026-03-18	10-K	0001213900-26-029500
8	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$8.0M	2024-12-31	2025-04-04	10-K	0001558370-25-004477
9	gross profit	us-gaap:GrossProfit	\$5.5M	2023-12-31	2025-04-04	10-K	0001558370-25-004477
10	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$8.7M	2023-12-31	2025-04-04	10-K	0001558370-25-004477
11	gross profit	us-gaap:GrossProfit	\$6.8M	2022-12-31	2024-04-01	10-K	0001558370-24-004559
12	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$11.2M	2022-12-31	2024-04-01	10-K	0001558370-24-004559
13	gross profit	us-gaap:GrossProfit	\$8.3M	2021-12-31	2023-04-17	10-K	0001558370-23-006079
14	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$13.6M	2021-12-31	2023-04-17	10-K	0001558370-23-006079
15	current assets	us-gaap:AssetsCurrent	\$5.4M	2025-12-31	2026-03-18	10-K	0001213900-26-029500
16	current liabilities	us-gaap:LiabilitiesCurrent	\$2.7M	2025-12-31	2026-03-18	10-K	0001213900-26-029500
17	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$87.6M	2025-12-31	2026-03-18	10-K	0001213900-26-029500
18	operating income	us-gaap:OperatingIncomeLoss	-\$10.5M	2025-12-31	2026-03-18	10-K	0001213900-26-029500
19	book equity	us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterests	\$6.8M	2025-12-31	2026-03-18	10-K	0001213900-26-029500
20	liabilities	us-gaap:Liabilities	\$2.7M	2025-12-31	2026-03-18	10-K	0001213900-26-029500
21	capital expenditure	us-gaap:PaymentsToAcquireProductiveAssets	\$43,000	2023-12-31	2025-04-04	10-K	0001558370-25-004477
22	depreciation amortization	us-gaap:Depreciation	\$121,000	2023-12-31	2025-04-04	10-K	0001558370-25-004477
23	operating income	us-gaap:OperatingIncomeLoss	-\$15.4M	2023-12-31	2025-04-04	10-K	0001558370-25-004477
24	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsDeductibleItems	\$11.4M	2023-12-31	2025-04-04	10-K	0001558370-25-004477
25	income tax	us-gaap:IncomeTaxExpenseBenefit	\$52,000	2023-12-31	2025-04-04	10-K	0001558370-25-004477
26	current assets	us-gaap:AssetsCurrent	\$10.3M	2023-12-31	2025-04-04	10-K	0001558370-25-004477
27	current liabilities	us-gaap:LiabilitiesCurrent	\$3.8M	2023-12-31	2025-04-04	10-K	0001558370-25-004477
28	current assets	us-gaap:AssetsCurrent	\$9.9M	2022-12-31	2024-04-01	10-K	0001558370-24-004559
29	current liabilities	us-gaap:LiabilitiesCurrent	\$7.5M	2022-12-31	2024-04-01	10-K	0001558370-24-004559
30	assets	us-gaap:Assets	\$10.7M	2023-12-31	2025-04-04	10-K	0001558370-25-004477
31	assets	us-gaap:Assets	\$11.1M	2022-12-31	2024-04-01	10-K	0001558370-24-004559
32	shares outstanding	dei:EntityCommonStockSharesOutstanding	7,018,528	2026-03-17	2026-03-18	10-K	0001213900-26-029500
33	shares outstanding	dei:EntityCommonStockSharesOutstanding	11,276,248	2025-04-02	2025-04-04	10-K	0001558370-25-004477